REGENXBIO
Seeking to improve lives through the curative potential of gene therapy.
Seeking to improve lives through the curative potential of gene therapy.
REGENXBIO Inc. is a leading biotechnology company founded in 2009, with a slogan of "Seeking to improve lives through the curative potential of gene therapy." The company is focused on the development, commercialization, and licensing of recombinant adeno‐associated virus (AAV) gene therapy within the Biopharma and Biotechnology industries. Their proprietary AAV gene delivery platform, the NAV® Technology Platform, includes exclusive rights to over 100 novel AAV vectors. Notably, they hold rights to AAV7, AAV8, AAV9, and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on their NAV Technology Platform.
The company seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. In their latest funding round on 06 March 2024, REGENXBIO secured $140.00M in Post-IPO Equity investment.
REGENXBIO operates from the United States.The company is attracting attention and investment, reflecting the growing interest in gene therapy and its potential to address previously untreatable conditions, making it an appealing prospect for venture capitalists.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $140.00M | - | 06 Mar 2024 | |
| Post-IPO Equity | $230.30M | - | 06 Jan 2021 | |
| Post-IPO Equity | Unknown | 1 |
|
01 Jan 2020 |
| Post-IPO Equity | $201.80M | - | 08 Aug 2018 | |
| Post-IPO Equity | $87.20M | - | 21 Mar 2017 |
No recent news or press coverage available for REGENXBIO.
We care about your data, and we'd love to use cookies make your experience better.
